Stefania Morganti

8PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 30, 2026
Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.

|Sep 15, 2025
Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes.

Mona Arabzadeh, Yi-Han Tang, Christelle Colin-Leitzinger

|Oct 09, 2024
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution.

Amy E Schade, Naiara Perurena, Yoona Yang

|Jan 08, 2024
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.

Stefania Morganti, Christopher J Gibson, Qingchun Jin

|Aug 07, 2023
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.

Eleonora Nicolò, Paolo Tarantino, Oriana D'Ecclesiis

|Oct 07, 2022
Emerging Targeted Therapies for Early Breast Cancer.

Ilana Schlam, Paolo Tarantino, Stefania Morganti

Pageof 2

Frequent Collaborators

3 joint publications

Giuseppe Curigliano

3 joint publications

Sara M Tolaney

2 joint publications

Paolo Tarantino

2 joint publications

Dario Trapani